Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc (“Amylin” or the “Company”) (Nasdaq- AMLN) relating to the proposed acquisition by Bristol-Myers Squibb Company. (“Bristol-Myers”). Under the terms of the transaction, Amylin shareholders will receive only $31.00 in cash for each of Amylin stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Amylin for not acting in the Company’s shareholders' best interests in connection with the sale process to Bristol-Myers. The Board of Directors may have failed to adequately shop the Company and may have undervalued Amylin resulting in harm to the Amylin shareholders. For example, an analyst has placed a $32.00 price target on Amylin stock. If you own shares of Amylin stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com visiting http://brodsky-smith.com/444-amln-amylin-pharmaceuticals-inc.html, or by calling toll free 877-LEGAL-90.